The post-Covid New Normal: a golden opportunity for the NHS?
Innovation, Life Sciences, NHS, NHSE, Ping Conference
0 Comment
NHSE
Bureaucracy and duplication: the reality of the PPRS
drug market access, Leela Barham, market access, medicines assessment, NHS, NHSE, Pharmaceutical Price Regulation Scheme, PPRS
0 Comment
Has the PPRS delivered on the aim of reducing bureaucracy and duplication?
UK pharma denied legal challenge to drugs bill cap – updated
ABPI, judicial review, market access, NHS, NHSE
0 Comment
Rejection of legal challenge an embarrassing blow, and means NHS England free to introduce new budget curbs.
Improved access? The reality of the PPRS
Leela Barham, NHS, NHSE, Pharmaceutical Price Regulation Scheme, PPRS
0 Comment
Keeping the UK branded medicines bill within affordable limits – has PPRS delivered?
Creating headroom: can cutting spend on low-value prescriptions fund new drugs?
Drug funding, Low-value prescriptions, market access, NHS, NHSE, patients
0 Comment
Can reducing NHS spending on ‘low-value’ prescriptions help fund new drugs?
Budget impact and cost effectiveness: alternatives to NICE and NHSE proposals
Highly Specialised Technology, HST, HTA, NHS, NHSE, NICE
0 Comment
A new way to capture when drugs are ‘cost effective’ but not ‘affordable’ looks set to be introduced in England.
Budget impact and cost effectiveness: Can the UK learn from ICER in the US?
Drug funding, Drug pricing, ICER, market access, NHS, NHSE, NICE
0 Comment
Leela Barham examines the approach of the Institute for Clinical and Economic Review.
The budget impact of new medicines
Budget Impact Test, Drug funding, HTA, market access, NHS, NHSE, NICE, PPRS, Technology Appraisal
0 Comment
What could be the impact of proposed new ‘budget impact threshold’ for drugs?
Fast-track appraisals and Managed Access Agreements
ema, European Medicines Agency, Health Technology Assessment, HTA, MAA, Managed Access Agreement, market access, NHS, NHS England, NHSE, NICE, pharma, priority medicines
0 Comment
Experts discuss England’s proposed ‘fast-track’ appraisals for new treatments, plus MAAs.
1 2